GILD Gilead Sciences
- Official Name: GILEAD SCIENCES, INC.
- Headquarters: 333 LAKESIDE DR, FOSTER CITY, CA, 94404-1147 US
- CEO: Daniel P. O'Day
- Website: gilead.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Lost by 0.483 | (1.466) - (0.983) | ||
| 2025-07-21 | 2 | Lost by 16.974 | (3.897) - 13.077 | ||
| 2025-07-28 | 3 | Won by 11.208 | 5.193 - (6.015) | ||
| 2025-07-29 | 2R | Won by 6.005 | 3.122 - (2.883) | ||
| 2025-08-04 | 4 | Won by 10.866 | 3.757 - (7.109) | ||
| 2025-08-06 | 1R | Lost by 2.037 | (1.575) - 0.462 | ||
| 2025-08-07 | 1R | Lost by 2.313 | (0.037) - 2.276 | ||
| 2025-08-11 | 5 | Lost by 9.440 | 4.369 - 13.809 | ||
| 2025-08-12 | 3R | Lost by 2.600 | (0.140) - 2.460 | ||
| 2025-08-18 | 6 | Lost by 1.131 | (0.968) - 0.163 | ||
| 2025-08-25 | 7 | Lost by 12.477 | (2.231) - 10.246 | ||
| 2025-09-01 | 8 | Lost by 2.403 | (1.026) - 1.377 | ||
| 2025-09-08 | 9 | Won by 2.447 | 2.716 - 0.269 | ||
| 2025-09-15 | 10 | Lost by 1.432 | (2.705) - (1.273) | ||
| 2025-09-22 | 11 | Lost by 7.729 | (0.044) - 7.685 | ||
| 2025-09-29 | 12 | Won by 0.133 | 0.114 - (0.019) | ||
| 2025-10-06 | 13 | Won by 5.571 | 0.719 - (4.852) | ||
| 2025-10-13 | 14 | Won by 1.694 TOTW | 3.790 - 2.096 | ||
| 2025-10-20 | 15 | Won by 2.549 | 4.238 - 1.689 |
Latest News
Yahoo - 2026-10-16
Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?
Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal...
Yahoo - 2026-10-16
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.
Yahoo - 2026-10-16
Coca-Cola, Visa and Mastercard Hit Records as Investors Rotate Out of Chip Stocks
Coca-Cola, Visa and Mastercard are among the stocks hitting records as investors look beyond the AI trade. Earnings could help broaden the rally.
Yahoo - 2026-10-16
3 Inflated Stocks Walking a Fine Line
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business impro...
Yahoo - 2026-10-15
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
Yahoo - 2026-10-15
Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.
AbbVie, meanwhile, closed just shy of a record high, with shares ticking up 0.6% to $283.40.
Yahoo - 2026-10-15
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif., October 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance...
CNBC - 2026-10-15
Final Trade: AEM, IEV, BABA, GILD
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Yahoo - 2026-10-15
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three nov...
Yahoo - 2026-10-15
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.
Yahoo - 2026-10-15
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prosp...
ChartMill - 2026-10-14
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Yahoo - 2026-10-14
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership?
Gilead Sciences (NasdaqGS:GILD) announced a collaboration with Vir Biotechnology to develop novel T cell engagers for solid tumors. The agreement gran...
ChartMill - 2026-10-14
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Yahoo - 2026-10-14
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and ...
Yahoo - 2026-10-14
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead Sciences (GILD)
Benzinga - 2026-10-14
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
Yahoo - 2026-10-14
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
SAN FRANCISCO, October 14, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover ...
Yahoo - 2026-10-14
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this lis...
Benzinga - 2026-10-14
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked T...
Benzinga - 2026-10-14
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking te...
Benzinga - 2026-10-13
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.27% on an annualized basis producing an average annual return of...
Yahoo - 2026-10-13
Earnings Preview: What to Expect From Gilead Sciences’ Report
Gilead Sciences is set to report its Q3 results soon, with analysts projecting a double-digit year-over-year decline in EPS.
Yahoo - 2026-10-12
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the ...
Yahoo - 2026-10-12
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced...
Yahoo - 2026-10-12
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a phy
Yahoo - 2026-10-12
Can Gilead (GILD) Stock Continue Rising in 2027?
Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cance...
Show more
Yahoo - 2026-10-11
Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?
Yahoo - 2026-10-09
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
Yahoo - 2026-10-09
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Yahoo - 2026-10-08
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Benzinga - 2026-10-08
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126
Benzinga - 2026-10-08
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Yahoo - 2026-10-07
Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?
Yahoo - 2026-10-07
Is Exelixis Stock Engineered To Make You Money?
Yahoo - 2026-10-07
Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff?
Yahoo - 2026-10-07
Stock Market Today: Dow Tumbles 450 Points As Yields Jump; Fed Minutes On Deck (Live Coverage)
Benzinga - 2026-10-07
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158
Benzinga - 2026-10-07
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170
Benzinga - 2026-10-07
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163
Yahoo - 2026-10-07
Gilead Sciences signs five-year DevOps agreement with Cognizant
Yahoo - 2026-10-06
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
SeekingAlpha - 2026-10-06
Gilead: Buying Growth Isn't Free, And The Discounted Cash Flow Model Knows It
Yahoo - 2026-10-05
BioMarin Appoints Cara Bauer as Chief People Officer
CNBC - 2026-10-05
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
ChartMill - 2026-10-05
Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support
Yahoo - 2026-10-05
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Benzinga - 2026-10-05
Nurix Gets $10M As Gilead Extends Drug Discovery Deal
Yahoo - 2026-10-02
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
ChartMill - 2026-10-02
Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup
Yahoo - 2026-10-01
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Yahoo - 2026-10-01
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo - 2026-09-30
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
Benzinga - 2026-09-30
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
Yahoo - 2026-09-29
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
SeekingAlpha - 2026-09-28
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Yahoo - 2026-09-28
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?
Yahoo - 2026-09-28
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?
Yahoo - 2026-09-28
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Yahoo - 2026-09-28
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Yahoo - 2026-09-28
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
Yahoo - 2026-09-27
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Yahoo - 2026-09-27
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
SeekingAlpha - 2026-09-25
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Benzinga - 2026-09-24
10 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-09-23
Gilead: HIV Growth Is Not Enough At The Current Price
Yahoo - 2026-09-22
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Yahoo - 2026-09-22
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
CNBC - 2026-09-22
Novo defends diversification push as CEO eyes deals beyond obesity
Yahoo - 2026-09-21
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Yahoo - 2026-09-21
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
Benzinga - 2026-09-21
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today
CNBC - 2026-09-21
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
Yahoo - 2026-09-20
Why Morgan Stanley likes Gilead's HIV prevention play
Yahoo - 2026-09-18
4 Biotech Stocks to Watch as Potential Takeover Targets
Yahoo - 2026-09-18
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Yahoo - 2026-09-17
Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Yahoo - 2026-09-17
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Yahoo - 2026-09-16
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
Yahoo - 2026-09-16
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
Yahoo - 2026-09-16
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Yahoo - 2026-09-15
Sector Update: Healthcare Stocks Ease Late Afternoon
Yahoo - 2026-09-15
Sector Update: Healthcare Stocks Lower Tuesday Afternoon
Yahoo - 2026-09-15
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
SeekingAlpha - 2026-09-15
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benzinga - 2026-09-15
Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean
Benzinga - 2026-09-15
Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters
Benzinga - 2026-09-15
Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027
Yahoo - 2026-09-15
Gilead Sciences Inc's Dividend Analysis
Yahoo - 2026-09-14
Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?
Yahoo - 2026-09-14
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Yahoo - 2026-09-11
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
SeekingAlpha - 2026-09-11
Dividend Champion, Contender, And Challenger Highlights: Week September 13
Benzinga - 2026-09-10
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Yahoo - 2026-09-10
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
SeekingAlpha - 2026-09-10
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Yahoo - 2026-09-10
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Benzinga - 2026-09-10
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
SeekingAlpha - 2026-09-09
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Yahoo - 2026-09-09
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Yahoo - 2026-09-09
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
Yahoo - 2026-09-09
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
Yahoo - 2026-09-09
Gilead launches research facility in US for new medicine development
SeekingAlpha - 2026-09-09
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Yahoo - 2026-09-08
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
Yahoo - 2026-09-08
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Yahoo - 2026-09-08
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
CNBC - 2026-09-08
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
Yahoo - 2026-09-07
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
Yahoo - 2026-09-07
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Yahoo - 2026-09-05
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Yahoo - 2026-09-04
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
ChartMill - 2026-09-04
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
Yahoo - 2026-09-04
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
Yahoo - 2026-09-03
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Yahoo - 2026-09-03
Is Gilead Sciences Stock Outperforming the S&P 500?
Yahoo - 2026-09-02
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Yahoo - 2026-09-01
Top Research Reports for Toyota Motor, CrowdStrike & Welltower
Yahoo - 2026-09-01
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Yahoo - 2026-09-01
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Yahoo - 2026-09-01
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Yahoo - 2026-08-31
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Yahoo - 2026-08-31
3 Unpopular Stocks with Open Questions
Benzinga - 2026-08-31
FDA Approves Gilead's New Single Tablet HIV Regimen
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Yahoo - 2026-08-28
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Yahoo - 2026-08-27
Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run
Yahoo - 2026-08-27
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
ChartMill - 2026-08-27
What's going on in today's after hours session: S&P500 movers
CNBC - 2026-08-27
FDA approves Gilead's daily HIV pill
Benzinga - 2026-08-27
Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
CNBC - 2026-08-27
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
Yahoo - 2026-08-27
What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?
SeekingAlpha - 2026-08-27
GSK: Still One Of My Top Healthcare Picks
Yahoo - 2026-08-26
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Yahoo - 2026-08-26
Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug
Yahoo - 2026-08-25
Eli Lilly Is Pulling Away From the Rest of Healthcare
Yahoo - 2026-08-25
3 Dividend Stocks to Hold for the Next 10 Years
Yahoo - 2026-08-25
3 Unprofitable Stocks with Questionable Fundamentals
Yahoo - 2026-08-24
GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict
Yahoo - 2026-08-24
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Yahoo - 2026-08-24
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition
Benzinga - 2026-08-24
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Yahoo - 2026-08-24
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Benzinga - 2026-08-24
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Yahoo - 2026-08-23
Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?
Yahoo - 2026-08-21
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Yahoo - 2026-08-20
Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
Yahoo - 2026-08-19
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
Yahoo - 2026-08-19
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
Yahoo - 2026-08-18
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Yahoo - 2026-08-18
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
Yahoo - 2026-08-17
Gilead yanks out a thorn in its side in major court ruling
Yahoo - 2026-08-16
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
SeekingAlpha - 2026-08-16
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Yahoo - 2026-08-14
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Yahoo - 2026-08-14
Gilead wins appeals court ruling against overseas drug imports
Yahoo - 2026-08-14
BofA biotech scorecard: Two buys and odd one out
CNBC - 2026-08-14
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
Yahoo - 2026-08-13
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Yahoo - 2026-08-13
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Yahoo - 2026-08-13
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run
Yahoo - 2026-08-13
Why Gilead Sciences (GILD) Is Back In The Spotlight
Yahoo - 2026-08-13
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Yahoo - 2026-08-12
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics
Yahoo - 2026-08-12
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Benzinga - 2026-08-12
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
Yahoo - 2026-08-11
3 Healthcare Stocks with Open Questions
Yahoo - 2026-08-11
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
Benzinga - 2026-08-11
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Yahoo - 2026-08-11
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Benzinga - 2026-08-11
Snowflake shares are trading lower. The company announced the appointment of Jonathan Beaulier as Chief Revenue Officer and reaffirmed its FY27 guidance.
Yahoo - 2026-08-11
Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration
Yahoo - 2026-08-10
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
SeekingAlpha - 2026-08-10
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Yahoo - 2026-08-10
GILD- An Attractive Biotech Stock with Solid Base Revenue Growth
Yahoo - 2026-08-08
Key HIV stat over 70% leaves BofA siding with Gilead
Yahoo - 2026-08-07
What Insmed Stock's Premium Is Actually Buying
Yahoo - 2026-08-07
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
SeekingAlpha - 2026-08-07
Amgen: The Market Is Underestimating Its Next Growth Phase
Yahoo - 2026-08-06
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
SeekingAlpha - 2026-08-06
Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings
Benzinga - 2026-08-05
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
Yahoo - 2026-08-05
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...
Yahoo - 2026-08-05
Kymera Therapeutics Q2 Earnings Call Highlights
Yahoo - 2026-08-05
Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat
Benzinga - 2026-08-05
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123
Yahoo - 2026-08-05
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth
Yahoo - 2026-08-05
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Benzinga - 2026-08-05
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Yahoo - 2026-08-05
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...
ChartMill - 2026-08-04
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance
Yahoo - 2026-08-04
Gilead Sciences Q2 Earnings Call Highlights
Yahoo - 2026-08-04
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics
SeekingAlpha - 2026-08-04
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Yahoo - 2026-08-04
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Yahoo - 2026-08-04
AHF Crowns Gilead Corporate Welfare King
Yahoo - 2026-08-04
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Yahoo - 2026-08-04
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story
Yahoo - 2026-08-04
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up
Yahoo - 2026-08-04
Gilead Sciences Announces Second Quarter 2026 Financial Results
Yahoo - 2026-08-04
Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes
Yahoo - 2026-08-04
Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
SeekingAlpha - 2026-08-04
Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
Benzinga - 2026-08-04
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Benzinga - 2026-08-04
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Yahoo - 2026-08-04
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?
Yahoo - 2026-08-04
Gilead Sciences, Inc. Q2 2026 Earnings Call Summary
Yahoo - 2026-08-04
Compugen Ltd. Q2 2026 Earnings Call Summary
Yahoo - 2026-08-04
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Yahoo - 2026-08-04
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
CNBC - 2026-08-03
Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers
Yahoo - 2026-08-03
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
Benzinga - 2026-08-03